These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
901 related articles for article (PubMed ID: 12223530)
21. Mediation of cell death by poly(ADP-ribose) polymerase-1. Koh DW; Dawson TM; Dawson VL Pharmacol Res; 2005 Jul; 52(1):5-14. PubMed ID: 15911329 [TBL] [Abstract][Full Text] [Related]
22. Role of Peroxynitrite-Induced Activation of Poly(ADP-Ribose) Polymerase (PARP) in Circulatory Shock and Related Pathological Conditions. Islam BU; Habib S; Ali SA; Moinuddin ; Ali A Cardiovasc Toxicol; 2017 Oct; 17(4):373-383. PubMed ID: 27990620 [TBL] [Abstract][Full Text] [Related]
23. Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Szabó C; Dawson VL Trends Pharmacol Sci; 1998 Jul; 19(7):287-98. PubMed ID: 9703762 [TBL] [Abstract][Full Text] [Related]
25. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations. Geraets L; Moonen HJ; Wouters EF; Bast A; Hageman GJ Biochem Pharmacol; 2006 Sep; 72(7):902-10. PubMed ID: 16870158 [TBL] [Abstract][Full Text] [Related]
26. Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation. Aguilar-Quesada R; Muñoz-Gámez JA; Martín-Oliva D; Peralta-Leal A; Quiles-Pérez R; Rodríguez-Vargas JM; Ruiz de Almodóvar M; Conde C; Ruiz-Extremera A; Oliver FJ Curr Med Chem; 2007; 14(11):1179-87. PubMed ID: 17504138 [TBL] [Abstract][Full Text] [Related]
27. Poly (ADP-ribose) polymerase: An Overview of Mechanistic Approaches and Therapeutic Opportunities in the Management of Stroke. Tiwari P; Khan H; Singh TG; Grewal AK Neurochem Res; 2022 Jul; 47(7):1830-1852. PubMed ID: 35437712 [TBL] [Abstract][Full Text] [Related]
28. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy. Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701 [TBL] [Abstract][Full Text] [Related]
29. The role of poly(ADP-ribose) polymerase-1 in CNS disease. Kauppinen TM; Swanson RA Neuroscience; 2007 Apr; 145(4):1267-72. PubMed ID: 17084037 [TBL] [Abstract][Full Text] [Related]
30. Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. Virág L; Szabó E; Gergely P; Szabó C Toxicol Lett; 2003 Apr; 140-141():113-24. PubMed ID: 12676457 [TBL] [Abstract][Full Text] [Related]
31. Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions. Beneke S; Diefenbach J; Bürkle A Int J Cancer; 2004 Oct; 111(6):813-8. PubMed ID: 15300792 [TBL] [Abstract][Full Text] [Related]
32. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia. Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382 [TBL] [Abstract][Full Text] [Related]
33. Role of nitrosative stress and poly(ADP-ribose) polymerase activation in myocardial reperfusion injury. Szabó G; Bährle S Curr Vasc Pharmacol; 2005 Jul; 3(3):215-20. PubMed ID: 16026318 [TBL] [Abstract][Full Text] [Related]
34. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy. Cepeda V; Fuertes MA; Castilla J; Alonso C; Quevedo C; Soto M; Pérez JM Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):39-53. PubMed ID: 18221025 [TBL] [Abstract][Full Text] [Related]